EGFR antibody
<p>Two cases of lymphangitic carcinomatosis as the primary symptom of colorectal carcinoma that achieved complete remission using combination anti-EGFR antibody therapy</p>
... anti-EGFR antibody therapy was limited in the treatment of patients with right-sided ...anti-EGFR antibody; meanwhile, the recommendation for right-sided carcinoma is either three cytotoxic ...
5
Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody
... lead to early discontinuation of treatment. But Anti- EGFR antibody drugs have been reported to have a marked therapeutic effect in patients who exhibit skin toxicities. Using the data in the present study, ...
6
Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR antibody to a fatal outcome
... Preclinical evidence exists for a possible correlation between EGFR-antibody therapy and impaired EGFR- mediated repair mechanisms in gastric and airway epithe- lial cells. The widespread, in general ...
6
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
... the EGFR signaling activity markers phosphorylated PRAS40 and phosphorylated ribosomal protein S6 as predictive markers for treatment efficacy of the EGFR-blocking antibody nimotuzumab in MGMT ...
13
Therapeutic anti EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas
... specific EGFR- vIII extracellular domain mutation (12, ...having EGFR kinase domain mutations, although they did have an objective response (41% ± 2%) radiographically and histologi- cally (22, ...the ...
8
Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report
... It is rarely reported that treatment with anti-EGFR antibody can cause LOC. Out of 4603 cases (11,069 ad- ministrations) from September 19, 2008, to October 2, 2011, only 3 cases were recorded in the ...
6
Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis
... over EGFR antibody because Nanotetrac is targeted to cancer cells that express α v β 3 and thus does not affect this cell surface target in healthy (nonmalignant) ...
6
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
... anti-EGFR antibody and bevacizumab sequentially (in either order) and experience progres- sion, their disease is permanently resistant to both the biologic and cytotoxic agents that have been adminis- ...
10
RNAi-based validation of antibodies for reverse phase protein arrays
... the EGFR-antibody example, the EGFR-knockdown was recognized less efficiently by the weaker ...from antibody 6 were comparable to the background signals obtained in control incubations without ...
11
Refining EGFR-monoclonal antibody treatment in colorectal cancer
... to EGFR-antibody therapy is in line with other retrospective studies[4-6], which also showed a positive association on outcome for the KRAS codon 13 ...
169
Original Article Clinical significance of EGFR expression in tumor stroma of NSCLC
... of EGFR in tumor stroma of NSCLC were investi- ...of EGFR was evaluated in 145 patients with NSCLC using two different antibodies (sc-03 from Santa Cruz Biotechnology and ab2430 from ...of EGFR ...
12
BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
... anti- EGFR antibody treatment (primary analysis cohort and liquid biopsy cohort) or refractory to prior anti- EGFR antibody treatment in patients with class 3 BRAF mutations (anti- EGFR ...
6
Prognostic Significance of EGFR Gene Amplification and Overexpression in Diffuse Astrocytomas—A Literature Study
... to EGFR gene amplification with some exceptions ...as EGFR gene amplification, co- expression of PTEN (phosphatase and tensin homologue deleted in chromosome 10) tumour-suppressor protein and activation of ...
10
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
... of EGFR in H292 and Ma-1 cells (Figure 2A), both of which manifest high levels of surface EGFR expression, consistent with the mode of action of this ...constitutive EGFR phosphorylation in H460 and ...
9
Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer
... receiving EGFR-targeted therapy beyond ...receiving EGFR-targeted therapy beyond PD (P = ...monoclonal antibody as first-line therapy, OS was correlated with subsequent availability of anti-VEGF ...
7
Preclinical Efficacy of Nimotuzumab, an Anti Egfr Monoclonal Antibody as a Single Agent Therapy in Human GBM u87mg Xenografts
... MIB-1 antibody (1:50) against the Ki-67 as described previously ...an antibody against CD31/PECAM-1 ...determine EGFR expression tumor sections were stained as described ...primary antibody ...
11
Epidermal Growth Factor Receptor Is Not Required for Human Cytomegalovirus Entry or Signaling
... for EGFR and  3 integrins in the context of HCMV entry ...However, EGFR-negative cell lines, such as hematopoietic cells, are known to be infected by ...for EGFR in HCMV entry and then examine any ...
7
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
... EGFR targeting TKIs and mAbs has been associated with several side effects, especially within organs with high levels of proliferation and EGFR expression, most notably the epidermis and intestinal lining. ...
10
Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
... Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible ...
10
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
... phosphorylated EGFR, and downstream phosphorylated molecules Akt and MAPK) and cellular proliferation was ...of EGFR antibodies to wild-type EGFR resulted in increased internalization and degradation ...
10